OS
PFS
Response
Rate
PSA 50
No. pts
Reff
Author
8.2 mo
NR
15.3%
31.5%
24
Clinical Genitourinary Cancer
2014
Avishay Sella
10.9 mo
4.4 mo
NR
35%
79
European Urology 2014
Nader Al Nakouzi
20.3 mo
5.5 mo
15%
41%
*37
European Urology 2014
Carmel J. Pezaro
12 mo
5 mo
14%
28%
#110
European Urology 2014
Orazio Caffo
11.8 mo
NR
NR
NR
36
Clinical Genitourinary Cancer
2015
Guru Sonpavde
13.0 mo vs
14.0 mo
p=0.65
NR
NR
34% vs 40%
p=0,53
***114
European Journal of Cancer
2015
Eric Van Soest
15,1 mo
2.8 mo
14.4%
39.2%
755
Lancet 2010
J.S de Bono
Cabazitaxel mantiene la eficacia tras docetaxel y AA
* Four patients received also enzalutamide
#
Sixteen patients received also enzalutamide
*** Prospective study
cabazitaxel
ABI/DOC o DOC/ABI
